Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695 is registered in ClinicalTrials.gov with A2 Biotherapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Lead sponsor
- A2 Biotherapeutics Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- April 3, 2024
- Completion date
- June 30, 2029
- Enrollment
- 474 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, colon cancer, colorectal adenocarcinoma, colorectal cancer, crc, lung cancer, mesom, mesothelioma, mesothelioma, malignant, non small cell lung cancer, non-small cell squamous lung cancer, nsclc, nsclc, recurrent, ovarian cancer, ovarian neoplasms, ovary cancer, pancreas cancer, pancreatic neoplasm, rectal cancer, solid tumor, adult